Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004912 | 0.85 | HCRTR1 (0.32) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16905401 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL16905404 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL16905403 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL16905405 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL16905402 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL16964987 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL1005463 | 0.77 | CHRM2 (0.40) | SMN1; SMN2 | |
| SCHEMBL1005464 | 0.77 | CHRM2 (0.40) | SMN1; SMN2 | |
| SCHEMBL1006280 | 0.77 | CHRM2 (0.40) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | SMN1; SMN2 291/4885HCRTR1 4646/4885HCRTR2 4411/4885 |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | SMN1; SMN2 291/4885HCRTR1 4646/4885HCRTR2 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.